18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies

Sara Sheikhbahaei, Krystyna M. Jones, Rudolf A. Werner, Roberto A. Salas-Fragomeni, Charles V. Marcus, Takahiro Higuchi, Steven P. Rowe, Lilja B. Solnes, Mehrbod S. Javadi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: This meta-analysis aims to establish the diagnostic performance of 18 F-NaF-PET/CT for the detection of bone metastases in prostate cancer patients. The performance of 18 F-NaF-PET/CT was compared with other imaging techniques in the same cohort of patients. Methods: A systematic search was performed in PubMed/Medline and EMBASE (last Updated, September 28, 2018). Studies with histopathology confirmation and/or clinical/imaging follow-up as reference standard were eligible for inclusion. Results: A total of 14 studies were included. Twelve studies including 507 patients provided per-patient basis information. The pooled sensitivity, specificity, diagnostic odds ratio (DOR) and the area under the summary receiver operating characteristics curve (AUC) of 18 F-NaF-PET/CT for the detection of bone metastases were 0.98 (95% CI 0.95–0.99), 0.90 (95% CI 0.86–0.93), 123.2 and 0.97, respectively. Seven studies provided the lesion-based accuracy information of 1812 lesions identified on 18 F-NaF-PET/CT with the pooled sensitivity, specificity, DOR and AUC of 0.97 (95% CI 0.95–0.98), 0.84 (95% CI 0.81–0.87), 206.8 and 0.97, respectively. The overall diagnostic performance of 18 F-NaF-PET/CT is superior to 99m Tc-bone scintigraphy (AUC 0.842; P < 0.001; four studies) and 99m Tc-SPECT (AUC 0.896; P < 0.001, four studies). Compared to 18 F NaF-PET/CT, whole-body MRI with diffusion-weighted imaging (DWI) was shown to have lower sensitivity (0.83, 95% CI 0.68–0.93), with no significant difference in the overall performance (AUC 0.947; P = 0.18, four studies). Conclusion: 18 F-NaF-PET/CT has excellent diagnostic performance in the detection of bone metastases in staging and restaging of high-risk prostate cancer patients. The performance of 18 F-NaF-PET/CT is superior to 99m Tc bone scintigraphy and SPECT, and comparable to DWI–MRI.

Original languageEnglish
JournalAnnals of nuclear medicine
DOIs
Publication statusAccepted/In press - Jan 1 2019
Externally publishedYes

Fingerprint

Area Under Curve
Meta-Analysis
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Single-Photon Emission-Computed Tomography
Radionuclide Imaging
Odds Ratio
Sensitivity and Specificity
Diffusion Magnetic Resonance Imaging
PubMed
ROC Curve

Keywords

  • F-NaF-PET/CT
  • Bone metastases
  • Prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer : a meta-analysis of diagnostic accuracy studies. / Sheikhbahaei, Sara; Jones, Krystyna M.; Werner, Rudolf A.; Salas-Fragomeni, Roberto A.; Marcus, Charles V.; Higuchi, Takahiro; Rowe, Steven P.; Solnes, Lilja B.; Javadi, Mehrbod S.

In: Annals of nuclear medicine, 01.01.2019.

Research output: Contribution to journalArticle

Sheikhbahaei, Sara ; Jones, Krystyna M. ; Werner, Rudolf A. ; Salas-Fragomeni, Roberto A. ; Marcus, Charles V. ; Higuchi, Takahiro ; Rowe, Steven P. ; Solnes, Lilja B. ; Javadi, Mehrbod S. / 18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer : a meta-analysis of diagnostic accuracy studies. In: Annals of nuclear medicine. 2019.
@article{608a62c8b21a4ff4a9c60259b06d927b,
title = "18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies",
abstract = "Purpose: This meta-analysis aims to establish the diagnostic performance of 18 F-NaF-PET/CT for the detection of bone metastases in prostate cancer patients. The performance of 18 F-NaF-PET/CT was compared with other imaging techniques in the same cohort of patients. Methods: A systematic search was performed in PubMed/Medline and EMBASE (last Updated, September 28, 2018). Studies with histopathology confirmation and/or clinical/imaging follow-up as reference standard were eligible for inclusion. Results: A total of 14 studies were included. Twelve studies including 507 patients provided per-patient basis information. The pooled sensitivity, specificity, diagnostic odds ratio (DOR) and the area under the summary receiver operating characteristics curve (AUC) of 18 F-NaF-PET/CT for the detection of bone metastases were 0.98 (95{\%} CI 0.95–0.99), 0.90 (95{\%} CI 0.86–0.93), 123.2 and 0.97, respectively. Seven studies provided the lesion-based accuracy information of 1812 lesions identified on 18 F-NaF-PET/CT with the pooled sensitivity, specificity, DOR and AUC of 0.97 (95{\%} CI 0.95–0.98), 0.84 (95{\%} CI 0.81–0.87), 206.8 and 0.97, respectively. The overall diagnostic performance of 18 F-NaF-PET/CT is superior to 99m Tc-bone scintigraphy (AUC 0.842; P < 0.001; four studies) and 99m Tc-SPECT (AUC 0.896; P < 0.001, four studies). Compared to 18 F NaF-PET/CT, whole-body MRI with diffusion-weighted imaging (DWI) was shown to have lower sensitivity (0.83, 95{\%} CI 0.68–0.93), with no significant difference in the overall performance (AUC 0.947; P = 0.18, four studies). Conclusion: 18 F-NaF-PET/CT has excellent diagnostic performance in the detection of bone metastases in staging and restaging of high-risk prostate cancer patients. The performance of 18 F-NaF-PET/CT is superior to 99m Tc bone scintigraphy and SPECT, and comparable to DWI–MRI.",
keywords = "F-NaF-PET/CT, Bone metastases, Prostate cancer",
author = "Sara Sheikhbahaei and Jones, {Krystyna M.} and Werner, {Rudolf A.} and Salas-Fragomeni, {Roberto A.} and Marcus, {Charles V.} and Takahiro Higuchi and Rowe, {Steven P.} and Solnes, {Lilja B.} and Javadi, {Mehrbod S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12149-019-01343-y",
language = "English",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",

}

TY - JOUR

T1 - 18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer

T2 - a meta-analysis of diagnostic accuracy studies

AU - Sheikhbahaei, Sara

AU - Jones, Krystyna M.

AU - Werner, Rudolf A.

AU - Salas-Fragomeni, Roberto A.

AU - Marcus, Charles V.

AU - Higuchi, Takahiro

AU - Rowe, Steven P.

AU - Solnes, Lilja B.

AU - Javadi, Mehrbod S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: This meta-analysis aims to establish the diagnostic performance of 18 F-NaF-PET/CT for the detection of bone metastases in prostate cancer patients. The performance of 18 F-NaF-PET/CT was compared with other imaging techniques in the same cohort of patients. Methods: A systematic search was performed in PubMed/Medline and EMBASE (last Updated, September 28, 2018). Studies with histopathology confirmation and/or clinical/imaging follow-up as reference standard were eligible for inclusion. Results: A total of 14 studies were included. Twelve studies including 507 patients provided per-patient basis information. The pooled sensitivity, specificity, diagnostic odds ratio (DOR) and the area under the summary receiver operating characteristics curve (AUC) of 18 F-NaF-PET/CT for the detection of bone metastases were 0.98 (95% CI 0.95–0.99), 0.90 (95% CI 0.86–0.93), 123.2 and 0.97, respectively. Seven studies provided the lesion-based accuracy information of 1812 lesions identified on 18 F-NaF-PET/CT with the pooled sensitivity, specificity, DOR and AUC of 0.97 (95% CI 0.95–0.98), 0.84 (95% CI 0.81–0.87), 206.8 and 0.97, respectively. The overall diagnostic performance of 18 F-NaF-PET/CT is superior to 99m Tc-bone scintigraphy (AUC 0.842; P < 0.001; four studies) and 99m Tc-SPECT (AUC 0.896; P < 0.001, four studies). Compared to 18 F NaF-PET/CT, whole-body MRI with diffusion-weighted imaging (DWI) was shown to have lower sensitivity (0.83, 95% CI 0.68–0.93), with no significant difference in the overall performance (AUC 0.947; P = 0.18, four studies). Conclusion: 18 F-NaF-PET/CT has excellent diagnostic performance in the detection of bone metastases in staging and restaging of high-risk prostate cancer patients. The performance of 18 F-NaF-PET/CT is superior to 99m Tc bone scintigraphy and SPECT, and comparable to DWI–MRI.

AB - Purpose: This meta-analysis aims to establish the diagnostic performance of 18 F-NaF-PET/CT for the detection of bone metastases in prostate cancer patients. The performance of 18 F-NaF-PET/CT was compared with other imaging techniques in the same cohort of patients. Methods: A systematic search was performed in PubMed/Medline and EMBASE (last Updated, September 28, 2018). Studies with histopathology confirmation and/or clinical/imaging follow-up as reference standard were eligible for inclusion. Results: A total of 14 studies were included. Twelve studies including 507 patients provided per-patient basis information. The pooled sensitivity, specificity, diagnostic odds ratio (DOR) and the area under the summary receiver operating characteristics curve (AUC) of 18 F-NaF-PET/CT for the detection of bone metastases were 0.98 (95% CI 0.95–0.99), 0.90 (95% CI 0.86–0.93), 123.2 and 0.97, respectively. Seven studies provided the lesion-based accuracy information of 1812 lesions identified on 18 F-NaF-PET/CT with the pooled sensitivity, specificity, DOR and AUC of 0.97 (95% CI 0.95–0.98), 0.84 (95% CI 0.81–0.87), 206.8 and 0.97, respectively. The overall diagnostic performance of 18 F-NaF-PET/CT is superior to 99m Tc-bone scintigraphy (AUC 0.842; P < 0.001; four studies) and 99m Tc-SPECT (AUC 0.896; P < 0.001, four studies). Compared to 18 F NaF-PET/CT, whole-body MRI with diffusion-weighted imaging (DWI) was shown to have lower sensitivity (0.83, 95% CI 0.68–0.93), with no significant difference in the overall performance (AUC 0.947; P = 0.18, four studies). Conclusion: 18 F-NaF-PET/CT has excellent diagnostic performance in the detection of bone metastases in staging and restaging of high-risk prostate cancer patients. The performance of 18 F-NaF-PET/CT is superior to 99m Tc bone scintigraphy and SPECT, and comparable to DWI–MRI.

KW - F-NaF-PET/CT

KW - Bone metastases

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85063037313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063037313&partnerID=8YFLogxK

U2 - 10.1007/s12149-019-01343-y

DO - 10.1007/s12149-019-01343-y

M3 - Article

C2 - 30877561

AN - SCOPUS:85063037313

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

ER -